MARKET

QGEN

QGEN

Qiagen
NYSE

Real-time Quotes | Nasdaq Last Sale

55.04
+0.29
+0.53%
Opening 10:46 09/23 EDT
OPEN
54.99
PREV CLOSE
54.75
HIGH
55.11
LOW
54.88
VOLUME
83.81K
TURNOVER
--
52 WEEK HIGH
59.00
52 WEEK LOW
45.33
MARKET CAP
12.58B
P/E (TTM)
26.78
1D
5D
1M
3M
1Y
5Y
Long Read Sequencing Market- Comprehensive Insights, Market Share, Industry Trends and Healthy Lifestyles during 2028
Research Nester has released a report titled which also includes some of the prominent market analyzing parameters such as industry growth drivers, restraints, supply and demand risk, market attractiveness, year-on-year (Y-O-Y) growth comparisons, market s...
AmericaNewsHour · 3h ago
LIVE MARKETS-DAX turns 40 but China spoils the party!
reuters.com · 3d ago
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now
Investors are optimistic about QIAGEN (QGEN) owing to impressive sales of diagnostic solutions and strong international growth.
Zacks · 09/16 13:38
Predisposition Biomarkers Market- Expected Growth and its Factors, CAGR, Industry Size, Business Prospects and Forecast 2030
Research Nester published a report titled which delivers detailed overview of the global predisposition biomarkers market in terms of market segmentation by type, application, end-user, and by region.
AmericaNewsHour · 09/16 06:17
Single Cell Genome Sequencing Market: Product Specification, Share, Size, Emerging Trends, Competitive Analysis and Forecast 2028
Research Nester published a report titled which delivers detailed overview of the global single cell genome sequencingmarket in terms of market segmentation by product, application, end user and by region.
AmericaNewsHour · 09/15 07:57
3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate
Zacks.com · 09/14 13:58
Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President's New OSHA Mandates
/PRNewswire/ --   -  More than 80 million workers in are now facing a being pushed by the Biden Administration through the Occupational Safety and Health Administration (OSHA) on employers with +100 employees. For many workplaces, this could mean a drast...
PR Newswire - PRF · 09/14 13:45
UPDATE 1-3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
reuters.com · 09/10 23:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QGEN. Analyze the recent business situations of Qiagen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QGEN stock price target is 57.73 with a high estimate of 75.00 and a low estimate of 47.50.
EPS
Institutional Holdings
Institutions: 396
Institutional Holdings: 130.39M
% Owned: 57.03%
Shares Outstanding: 228.64M
TypeInstitutionsShares
Increased
83
10.96M
New
33
4.55M
Decreased
104
10.41M
Sold Out
44
1.72M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.86%
Pharmaceuticals & Medical Research
+1.08%
Key Executives
Chairman - Supervisory/Director/Independent Director
Lawrence Rosen
Chief Executive Officer/Managing Director/Executive Board
Thierry Bernard
Chief Financial Officer/Managing Director/Executive Board
Roland Sackers
Independent Director/Supervisory Board
Metin Colpan
Independent Director/Supervisory Board
Ross Levine
Independent Director/Supervisory Board
Elaine Mardis
Independent Director/Supervisory Board
Elizabeth Tallett
Supervisory Board
Thomas Ebeling
Supervisory Board
Toralf Haag
Declaration Date
Dividend Per Share
Ex-Div Date
01/18/2017
Dividend USD 1.08
01/25/2017
About QGEN
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Webull offers kinds of Qiagen NV stock information, including NYSE:QGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QGEN stock methods without spending real money on the virtual paper trading platform.